
Partnering revitalized at the BioFit2022 – in Strasbourg and online
A biologist, a CEO, and a venture capitalist enter the BioFit2022 event...., while this may sound like the beginning of a great joke, it fits the...

Roche withdraws checkpoint blocker from the market
Switzerland’s Hoffmann La Roche AG no longer markets its cancer immunotherapy atezolizumab (Tecentriq) for the treatment of urothelial carcinoma in...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

Collaboration to develop mRNA vaccine against betacoronaviruses
Ethris GmbH a German company specialising in the development of mRNA vaccines, announced their collaboration with DIOSynVax Ltd., an English biotech...

INDUSTRIA BIOTEC 2023 with a broader perspective
At this year's INDUSTRIA BIOTEC – a European industry meeting that took place at the KINDL Centre for Contemporary Art in Berlin at the beginning of...

EpiEndo Pharmaceuticals pushes COPD candidate
The Icelandic inflammation specialist received regulatory approval for its Phase IIa trial of Barriolide™ (EP395) in patients with Chronic...

Memo Therapeutics and Ono Pharmaceutical enter partnership
Under the terms of the agreement, Memo Therapeutics AG will leverage its microfluidic single-cell molecular cloning and screening technologies to...